MEDIA PERSPECTIVE: Carat’s Pfizer coup may push parents to look beyond US

If ever there was a story to get the new year off to an agenda-setting bang, it was the news that Carat has won the dollars 200 million US media business for Pfizer.

If ever there was a story to get the new year off to an

agenda-setting bang, it was the news that Carat has won the dollars 200

million US media business for Pfizer.

The implications for the US market are well rehearsed in this week’s

Media Forum. In awarding what is one of the US’s bigger media accounts

to a genuine media independent, Pfizer’s decision is something of a


The manoeuvre also helps drive home the inevitability of the standalone

media operation in the US.

Of course, the media specialist is not new in the States, and the big

agency groups are slowly waking up to the idea of spinning off their

media operations into branded units. Yet rarely does a US advertiser of

real size take full advantage of this independence to hand its media

assignment to a media operation unassociated with its creative agency of


But perhaps the most significant thing about the Carat coup is the

implication for its rivals outside the US. As the strongest of the

European networks, taking roughly 15 per cent of the European media

market, Carat has dominated media on this side of the Atlantic. Until

recently, though, Carat had little claim to territories beyond Europe,

providing some comfort to rivals with US parentage.

Yet while those US parents have dragged their feet on marshalling their

global media forces - much to the frustration of their European media

executives - Carat has now invaded their domestic playpen. It can now

claim top ten status in the US at a time when its European counterparts

are still battling against the lethargy and naivety of their US


But Carat’s triumph could hold some real benefits for European media

players. For all those US giants who have long dismissed both the idea

of media independents and the threat of the European proponents, the

Pfizer decision should at least rattle the skeletons in some cupboards.

And that can only be good news for their European media outposts.

It is surely only a matter of time before Carat is pitching for an

advertiser’s business on both sides of the Atlantic. And with the might

of its European credentials behind it, that would make Carat a

formidable opponent. Perhaps this will prompt the American agencies to

finally try to get their international media operations in order. And

that doesn’t just entail sticking flags on a map.

The Pfizer win suggests strongly that Carat’s US operation has the

professionalism that has characterised its European operations. But

Carat’s real trump card is its consistency of brand, not only in terms

of systems and service, but also identity. While most of the big

US-owned European media networks have to content themselves with a

threadbare international network hampered by US executives, whose grasp

of media as a business wouldn’t do justice to a junior in a UK agency,

Carat is forging a coherent global proposition.

Before commenting please read our rules for commenting on articles.

If you see a comment you find offensive, you can flag it as inappropriate. In the top right-hand corner of an individual comment, you will see 'flag as inappropriate'. Clicking this prompts us to review the comment. For further information see our rules for commenting on articles.

comments powered by Disqus